ICU Medical, Inc. (ICUI)
| Market Cap | 3.07B -7.8% |
| Revenue (ttm) | 2.16B -10.9% |
| Net Income | 46.34M |
| EPS | 1.85 |
| Shares Out | 24.99M |
| PE Ratio | 66.53 |
| Forward PE | 49.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,607 |
| Open | 122.25 |
| Previous Close | 123.23 |
| Day's Range | 121.30 - 125.01 |
| 52-Week Range | 107.00 - 160.29 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 169.00 (+37.44%) |
| Earnings Date | May 7, 2026 |
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinf... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ICUI stock is "Strong Buy." The 12-month stock price target is $169.0, which is an increase of 37.44% from the latest price.
News
ICU Medical reports Q1 adjusted EPS $1.72, consensus $1.75
Reports Q1 revenue $530.23M, consensus $531.12M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “First quarter results were generally in line with our expectations.”
ICU Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% organic revenue growth, record infusion systems sales, and 41% gross margin, with adjusted EPS up 15% year-over-year. Full-year guidance for EBITDA, EPS, and free cash flow is reiterated, despite oil and tariff headwinds, as integration and innovation initiatives progress.
ICU Medical Announces First Quarter 2026 Results
SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial resu...
ICU Medical price target lowered to $164 from $180 at KeyBanc
KeyBanc lowered the firm’s price target on ICU Medical (ICUI) to $164 from $180 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes…
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of...
ICU Medical price target lowered to $163 from $178 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on ICU Medical (ICUI) to $163 from $178 and keeps an Overweight rating on the shares. In addition to updated…
ICU Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has evolved into a global pure-play infusion leader, leveraging innovation and market consolidation for growth. Consumables and infusion systems segments are driving reliable earnings, with new products and software enhancing value. Margin expansion, tariff refunds, and share repurchases are key financial priorities.
ICU Medical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management reaffirmed EBITDA guidance and mid-single-digit growth for core segments, with margin expansion expected as integration and cost initiatives progress. Pump upgrades and consumables innovation are key drivers, while free cash flow and capital returns should improve as integration costs decline.
ICU Medical Transcript: 47th Annual Raymond James Institutional Investor Conference
A leading infusion therapy company highlighted its strong market position, ongoing innovation, and financial recovery post-acquisition. New unified pump platforms and incremental consumables innovation are driving growth, with margin expansion and improved cash flow expected as integration and tariff costs decline.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its particip...
ICU Medical price target raised to $178 from $172 at Piper Sandler
Piper Sandler raised the firm’s price target on ICU Medical (ICUI) to $178 from $172 and keeps an Overweight rating on the shares following quarterly results. Guidance for 2026 bracketed…
ICU Medical price target raised to $180 from $175 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on ICU Medical (ICUI) to $180 from $175 and keeps an Overweight rating on the shares given higher estimates. The firm…
ICU Medical sees FY26 adjusted EPS $7.75-$8.45, consensus $8.01
Sees FY26 adjusted EBITDA $400M-$430M. The company said, “For fiscal year 2026 the Company estimates GAAP net income to be in the range of $26 million to $44 million and…
ICU Medical Earnings Call Transcript: Q4 2025
Q4 2025 saw 2% organic revenue growth and strong operational results in consumables and systems, despite reported declines from JV deconsolidation and tariff headwinds. 2026 guidance calls for low- to mid-single-digit organic growth, margin expansion, and improved free cash flow as integration projects conclude.
ICU Medical reports Q4 adjusted EPS $1.91, consensus $1.69
Reports Q4 revenue $540.7M, consensus $541.2M. Vivek Jain, ICU Medical’s (ICUI) CEO, said, “Fourth quarter results were generally in line with our expectations.”
ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance
SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
ICU Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
A focused IV therapy company is leveraging innovation, strategic M&A, and targeted market niches to drive growth and margin improvement. New integrated pump systems and consumables are fueling commercial momentum, with financials and operational integration nearing key targets.
ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company...
ICU Medical Transcript: Piper Sandler 37th Annual Healthcare Conference
U.S. hospital volumes and capital spending remain healthy, supporting steady growth in consumables and infusion pumps. Integrated pump and software solutions are driving competitive wins, with a major pump replacement cycle expected to start in late 2026. Margin improvements and debt reduction continue, with future focus on software integration and potential stock buybacks.
ICU Medical management to meet with KeyBanc
Meeting to be held on December 1 in Milwaukee on in Chicago on December 2 hosted by KeyBanc.
ICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN CLEMENTE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company...
ICU Medical price target raised to $175 from $173 at KeyBanc
KeyBanc raised the firm’s price target on ICU Medical (ICUI) to $175 from $173 on higher estimates, while keeping an Overweight rating on the shares. The firm remains encouraged by…
ICU Medical price target raised to $172 from $153 at Piper Sandler
Piper Sandler raised the firm’s price target on ICU Medical (ICUI) to $172 from $153 and keeps an Overweight rating on the shares. The firm notes ICU reported Q3 results,…
ICU Medical reports Q3 adjusted EPS $2.03, consensus $1.43
Reports Q3 revenue $536.99M, consensus $511.48M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “We are pleased with our third quarter results.”